[1]
|
Kuroki, L. and Guntupalli, S.R. (2020) Treatment of Epithelial Ovarian Cancer. BMJ, 371, M3773. https://doi.org/10.1136/bmj.m3773
|
[2]
|
Reid, B.M., Permuth, J.B. and Sellers, T.A. (2017) Epidemiology of Ovarian Cancer: A Review. Cancer Biology & Medicine, 14, 9-32.
|
[3]
|
Høgdall, E.V., Christensen, L., Høgdall, C.K., et al. (2007) Prognostic Value of Estrogen Receptor and Progesterone Receptor Tumor Expression in Danish Ovarian Cancer Patients: From the “MALOVA” Ovarian Cancer Study. Oncology Reports, 18, 1051-1059.
|
[4]
|
Wang, M., Zhang, J. and Wu, Y. (2023) Tumor Metabolism Rewiring in Epithelial Ovarian Cancer. Journal of Ovarian Research, 16, Article No. 108. https://doi.org/10.1186/s13048-023-01196-0
|
[5]
|
Di Palma, T., Filippone, M.G., Pierantoni, G.M., et al. (2013) Pax8 Has a Critical Role in Epithelial Cell Survival and Proliferation. Cell Death & Disease, 4, e729. https://doi.org/10.1038/cddis.2013.262
|
[6]
|
Siegel, R.L., Miller, K.D., Wagle, N.S., Wagle, N.S., et al. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. https://doi.org/10.3322/caac.21763
|
[7]
|
Eckert, M.A., Pan, S., Hernandez, K.M., et al. (2016) Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discovery, 6, 1342-1351. https://doi.org/10.1158/2159-8290.CD-16-0607
|
[8]
|
Ducie, J., Dao, F., Considine, M., et al. (2017) Molecular Analysis of High-Grade Serous Ovarian Carcinoma with and without Associated Serous Tubal Intra-Epithelial Carcinoma. Nature Communications, 8, Article No. 990. https://doi.org/10.1038/s41467-017-01217-9
|
[9]
|
Karnezis, A.N., Cho, K.R., Gilks, C.B., et al. (2017) The Disparate Origins of Ovarian Cancers: Pathogenesis and Prevention Strategies. Nature Reviews Cancer, 17, 65-74. https://doi.org/10.1038/nrc.2016.113
|
[10]
|
Dai, L., Song, Q., Li, L., et al. (2001) Expression of Cytokeratin 7 and 20 in Ovarian Metastatic Carcinomas. Chinese Journal of Pathology, 30, 114-117.
|
[11]
|
Schlüter, C., Duchrow, M., Wohlenberg, C., et al. (1993) The Cell Proliferation-Associated Antigen of Antibody Ki-67: A Very Large, Ubiquitous Nuclear Protein with Numerous Repeated Elements, Representing a New Kind of Cell Cycle-Maintaining Proteins. Journal of Cell Biology, 123, 513-522. https://doi.org/10.1083/jcb.123.3.513
|
[12]
|
Libé, R., Pais, A., Violon, F., et al. (2023) Positive Correlation between 18F-FDG Uptake and Tumor-Proliferating Antigen Ki-67 Expression in Adrenocortical Carcinomas. Clinical Nuclear Medicine, 48, 381-386. https://doi.org/10.1097/RLU.0000000000004593
|
[13]
|
Zhang, M., Meng, L., Zhang, Z., et al. (2022) The Relationships of OSBPL3 Expression with KI-67 Expression and KRAS Mutations in CRC: Implications for Diagnosis and Prognosis. BMC Med Genomics, 15, Article No. 259. https://doi.org/10.1186/s12920-022-01402-w
|
[14]
|
Qiu, D., Cai, W., Zhang, Z., Li, H. and Zhou, D. (2019) High Ki-67 Expression Is Significantly Associated with Poor Prognosis of Ovarian Cancer Patients: Evidence from a Meta-Analysis. Archives of Gynecology and Obstetrics, 299, 1415-1427. https://doi.org/10.1007/s00404-019-05082-3
|
[15]
|
Levine, A.J. (2020) P53: 800 Million Years of Evolution and 40 Years of Discovery. Nature Reviews Cancer, 20, 471-480. https://doi.org/10.1038/s41568-020-0262-1
|
[16]
|
Kastenhuber, E.R. and Lowe, S.W. (2017) Putting P53 in Context. Cell, 170, 1062-1078. https://doi.org/10.1016/j.cell.2017.08.028
|
[17]
|
Schlomm, T. (2020) Ergebnisse des “ICGC/TCGA Pan-Cancer Analysis of the Whole Genomes” (PCWAG)-Konsortiums [Results of the CGC/TCGA Pan-Cancer Analysis of the Whole Genomes (PCAWG) Consortium]. Der Urologe, 59, 1552-1553. https://doi.org/10.1007/s00120-020-01373-9
|
[18]
|
Bykov, V.J.N., Eriksson, S.E., Bianchi, J., et al. (2018) Targeting Mutant P53 for Efficient Cancer Therapy. Nature Reviews Cancer, 18, 89-102. https://doi.org/10.1038/nrc.2017.109
|
[19]
|
Sullivan, K.D., Galbraith, M.D., Andrysik, Z., et al. (2018) Mechanisms of Transcriptional Regulation by P53. Cell Death & Differentiation, 25, 133-143. https://doi.org/10.1038/cdd.2017.174
|
[20]
|
Wang, C.K., Chen, T.J., Tan, G.Y.T., et al. (2023) MEX3A Mediates P53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis. Cancer Research, 83, 251-263. https://doi.org/10.1158/0008-5472.CAN-22-1159
|
[21]
|
Shi, H.R. and Zhang, R.T. (2009) Expression and Significance of P53, P21WAF1 and CDK1 Proteins in Epithelial Ovarian Cancer. Chinese Journal of Cancer, 28, 882-885. https://doi.org/10.5732/cjc.008.10417
|
[22]
|
Okal, A., Cornillie, S., Matissek, S.J., et al. (2014) Re-Engineered P53 Chimera with Enhanced Homo-Oligomerization That Maintains Tumor Suppressor Activity. Molecular Pharmaceutics, 11, 2442-2452. https://doi.org/10.1021/mp500202p
|
[23]
|
Havrilesky, L.J., Alvarez, A.A., Whitaker, R.S., et al. (2001) Loss of Expression of the P16 Tumor Suppressor Gene Is More Frequent in Advanced Ovarian Cancers Lacking P53 Mutations. Gynecologic Oncology, 83, 491-500. https://doi.org/10.1006/gyno.2001.6464
|
[24]
|
Němejcová, K., Šafanda, A., Bártů, M.K., et al. (2023) A Comprehensive Immunohistochemical Analysis of 26 Markers in 250 Cases of Serous Ovarian Tumors. Diagnostic Pathology, 18, Article No. 32. https://doi.org/10.1186/s13000-023-01317-9
|
[25]
|
Makarla, P.B., Saboorian, M.H., Ashfaq, R., et al. (2005) Promoter Hypermethylation Profile of Ovarian Epithelial Neoplasms. Clinical Cancer Research, 11, 5365-5369. https://doi.org/10.1158/1078-0432.CCR-04-2455
|
[26]
|
Katsaros, D., Cho, W., Singal, R., et al. (2004) Methylation of Tumor Suppressor Gene P16 and Prognosis of Epithelial Ovarian Cancer. Gynecologic Oncology, 94, 685-692. https://doi.org/10.1016/j.ygyno.2004.06.018
|
[27]
|
Gessler, M., Poustka, A., et al. (1990) Homozygous Deletion in Wilms Tumours of a Zinc-Finger Gene Identified by Chromosome Jumping. Nature, 343, 774-778. https://doi.org/10.1038/343774a0
|
[28]
|
McCluggage, W.G. (2011) Morphological Subtypes of Ovarian Carcinoma: A Review with Emphasis on New Developments and Pathogenesis. Pathology, 43, 420-432. https://doi.org/10.1097/PAT.0b013e328348a6e7
|
[29]
|
McCluggage, W.G. (2004) WT1 Is of Value in Ascertaining the Site of Origin of Serous Carcinomas within the Female Genital Tract. International Journal of Gynecological Pathology, 23, 97-99. https://doi.org/10.1097/00004347-200404000-00002
|
[30]
|
Hohenstein, P. and Hastie, N.D. (2006) The Many Facets of the Wilms’ Tumour Gene, WT1. Human Molecular Genetics, 15, R196-R201. https://doi.org/10.1093/hmg/ddl196
|
[31]
|
Rekhi, B., Deodhar, K.K., Menon, S., et al. (2018) Napsin A and WT 1 Are Useful Immunohistochemical Markers for Differentiating Clear Cell Carcinoma Ovary from High-Grade Serous Carcinoma. APMIS, 126, 45-55. https://doi.org/10.1111/apm.12784
|
[32]
|
Zarychta, E., Lepinay, K., Szubert, S., et al. (2020) Wilms’ Tumor 1 Antigen Immunoreactivity in Epithelial Ovarian Cancer—Diagnostic and Prognostic Value. Folia Histochemica et Cytobiologica, 58, 198-207. https://doi.org/10.5603/FHC.a2020.0022
|
[33]
|
Stigbrand, T. (2001) The Versatility of Cytokeratins as Tumor Markers. Tumor Biology, 22, 1-3. https://doi.org/10.1159/000030148
|
[34]
|
Li, M., Shang, Y.-X., Wei, B. and Yang, Y.-G. (2011) The Effect of Substance P on Asthmatic Rat Airway Smooth Muscle Cell Proliferation, Migration, and Cytoplasmic Calcium Concentration in Vitro. Journal of Inflammation (London), 8, 18.
|
[35]
|
Dum, D., Menz, A., et al. (2022) Cytokeratin 7 and Cytokeratin 20 Expression in Cancer: A Tissue Microarray Study on 15,424 Cancers. Experimental and Molecular Pathology, 126, Article ID: 104762. https://doi.org/10.1016/j.yexmp.2022.104762
|
[36]
|
Ascoli, V., Taccogna, S., et al. (1995) Utility of Cytokeratin 20 in Identifying the Origin of Metastatic Carcinomas in Effusions. Diagnostic Cytopathology, 12, 303-308. https://doi.org/10.1002/dc.2840120404
|
[37]
|
Shin, J.H., Bae, J.H., Lee, A., et al. (2010) CK7, CK20, CDX2 and MUC2 Immunohistochemical Staining Used to Distinguish Metastatic Colorectal Carcinoma Involving Ovary from Primary Ovarian Mucinous Adenocarcinoma. Japanese Journal of Clinical Oncology, 40, 208-213. https://doi.org/10.1093/jjco/hyp150
|
[38]
|
Pasternak, S., Carter, M.D., Ly, T.Y., et al. (2018) Immunohistochemical Profiles of Different Subsets of Merkel Cell Carcinoma. Human Pathology, 82, 232-238. https://doi.org/10.1016/j.humpath.2018.07.022
|
[39]
|
Fei, F., Li, C., Cao, Y., et al. (2019) CK7 Expression Associates with the Location, Differentiation, Lymph Node Metastasis, and the Dukes’ Stage of Primary Colorectal Cancers. Journal of Cancer, 10, 2510-2519. https://doi.org/10.7150/jca.29397
|
[40]
|
Kim, M.A., Lee, H.S., Yang, H.K., et al. (2004) Cytokeratin Expression Profile in Gastric Carcinomas. Human Pathology, 35, 576-581. https://doi.org/10.1016/j.humpath.2003.12.007
|
[41]
|
Bai, S., Lindberg, J., Whalen, G., et al. (2021) Utility of HNF-1B and a Panel of Lineage-Specific Biomarkers to Optimize the Diagnosis of Pancreatic Ductal Adenocarcinoma. American Journal of Cancer Research, 11, 858-865.
|
[42]
|
Sree, U.D., Prayaga, A.K., Reddy, V.V., et al. (2022) Differential Expression of CK7, CK20, CDX2 in Intestinal and Pancreatobiliary Types of Preriampullary Carcinoma. Indian Journal of Pathology and Microbiology, 65, 42-48.
|
[43]
|
Ji, R., Li, Y., He, C., et al. (2020) Detection and Analysis of Multiple Biomarkers in Ovarian Cancer: Clinical Significance in Diagnosis, Treatment, and Prognosis Evaluation. Gland Surgery, 9, 2175-2186. https://doi.org/10.21037/gs-20-811
|
[44]
|
何娟, 黄林, 孙奇, 等. 检测原发性卵巢癌和转移性卵巢癌CDX2、CK7、CA_(125)表达的临床意义[J]. 实用妇产科杂志, 2017, 33(2): 141-144.
|
[45]
|
孙凯旋, 陈曦, 陈说, 等. CK7和CA125在人卵巢癌的表达及意义[J]. 解剖科学进展, 2014, 20(3): 237-239 245. https://doi.org/10.16695/j.cnki.1006-2947.2014.03.017
|
[46]
|
潘秀芳, 郑志昂, 麦燕. 血清附睾蛋白4、糖类抗原125及19-9水平在老年卵巢癌诊断及病理类型鉴别中的临床价值[J]. 中国老年学杂志, 2015, 35(12): 3343-3344.
|